NL8201022A - Azaspiroalkaandionen; werkwijze voor het bereiden daarvan; farmaceutische preparaten; werkwijze voor het oproepen van een tranquilizereffect. - Google Patents
Azaspiroalkaandionen; werkwijze voor het bereiden daarvan; farmaceutische preparaten; werkwijze voor het oproepen van een tranquilizereffect. Download PDFInfo
- Publication number
- NL8201022A NL8201022A NL8201022A NL8201022A NL8201022A NL 8201022 A NL8201022 A NL 8201022A NL 8201022 A NL8201022 A NL 8201022A NL 8201022 A NL8201022 A NL 8201022A NL 8201022 A NL8201022 A NL 8201022A
- Authority
- NL
- Netherlands
- Prior art keywords
- formula
- pharmaceutically acceptable
- compound
- butyl
- acid addition
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 41
- 230000002936 tranquilizing effect Effects 0.000 title claims description 8
- 239000003204 tranquilizing agent Substances 0.000 title claims description 5
- 230000000694 effects Effects 0.000 title claims description 4
- 229940125725 tranquilizer Drugs 0.000 title claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000000543 intermediate Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- -1 heterocyclic carbon compounds Chemical class 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000701 neuroleptic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- YJIRDHXJRYYJHD-UHFFFAOYSA-N decane-2,4-dione;hydrochloride Chemical compound Cl.CCCCCCC(=O)CC(C)=O YJIRDHXJRYYJHD-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004006 stereotypic behavior Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- YRTHJMQKDCXPAY-UHFFFAOYSA-N azaspirodecanedione Chemical compound C1C(=O)NC(=O)CC11CCCC1 YRTHJMQKDCXPAY-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical class O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/244,426 US4320131A (en) | 1981-03-16 | 1981-03-16 | N-[(4-Phenyl-1,2,3,6-tetrahydropyridin-1-yl)alkylene]azaspiroalkanediones and N-[(4-hydroxy-4-phenylpiperidin-1-yl)alkylene]azaspiroalkanediones |
| US24442681 | 1981-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8201022A true NL8201022A (nl) | 1982-10-18 |
Family
ID=22922718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8201022A NL8201022A (nl) | 1981-03-16 | 1982-03-11 | Azaspiroalkaandionen; werkwijze voor het bereiden daarvan; farmaceutische preparaten; werkwijze voor het oproepen van een tranquilizereffect. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US4320131A (en, 2012) |
| JP (1) | JPS57165384A (en, 2012) |
| KR (1) | KR880001557B1 (en, 2012) |
| AT (1) | AT381939B (en, 2012) |
| AU (1) | AU535385B2 (en, 2012) |
| BE (1) | BE892502A (en, 2012) |
| CA (1) | CA1192556A (en, 2012) |
| CH (2) | CH657365A5 (en, 2012) |
| CY (1) | CY1372A (en, 2012) |
| DE (1) | DE3209534A1 (en, 2012) |
| DK (1) | DK161322C (en, 2012) |
| ES (1) | ES510448A0 (en, 2012) |
| FI (1) | FI71317C (en, 2012) |
| FR (1) | FR2501689B1 (en, 2012) |
| GB (1) | GB2094801B (en, 2012) |
| GR (1) | GR76113B (en, 2012) |
| HK (1) | HK4688A (en, 2012) |
| HU (2) | HU193379B (en, 2012) |
| IE (1) | IE52789B1 (en, 2012) |
| IL (1) | IL65254A0 (en, 2012) |
| IT (1) | IT1148145B (en, 2012) |
| KE (1) | KE3710A (en, 2012) |
| LU (1) | LU84012A1 (en, 2012) |
| NL (1) | NL8201022A (en, 2012) |
| NZ (1) | NZ199944A (en, 2012) |
| PH (1) | PH18182A (en, 2012) |
| PT (1) | PT74584B (en, 2012) |
| SE (2) | SE449100B (en, 2012) |
| SG (1) | SG30887G (en, 2012) |
| YU (1) | YU43789B (en, 2012) |
| ZA (1) | ZA821541B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2660407B2 (ja) * | 1986-09-26 | 1997-10-08 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5153206A (en) * | 1988-12-02 | 1992-10-06 | Pfizer Inc. | Arylpiperidine derivatives |
| US5137894A (en) * | 1991-12-05 | 1992-08-11 | New James S | 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US355877A (en) * | 1887-01-11 | Waltee n | ||
| FR3013E (fr) * | 1902-04-03 | 1904-08-12 | William Henry Hoyle | Perfectionnements au procédé et aux machines pour la fabrication de matières fibreuses connues sous le nom de fils "frottés" |
| US3106552A (en) * | 1960-07-19 | 1963-10-08 | Geschickter Fund Med Res | Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation |
| US3432499A (en) * | 1965-04-02 | 1969-03-11 | Geschickter Fund Med Res | Trifluoromethylazaspiranes and azaspirane diones |
| US3398151A (en) * | 1966-02-01 | 1968-08-20 | Mead Johnson & Co | Azaspirodecanediones and azaspiroundecanediones |
| US3558777A (en) * | 1968-06-21 | 1971-01-26 | Mead Johnson & Co | Pharmacologic processes and compositions containing azaspirodecanediones and azaspiroundecanediones |
| BE759371A (fr) * | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| CH547802A (de) * | 1970-06-19 | 1974-04-11 | Hoffmann La Roche | Verfahren zur herstellung von tetrahydropyridinderivaten. |
| US3976776A (en) * | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4250175A (en) * | 1977-10-31 | 1981-02-10 | Mccall John M | Methods of treating psychosis |
| US4179510A (en) * | 1977-10-31 | 1979-12-18 | The Upjohn Company | Methods of treating psychosis |
| US4218456A (en) * | 1978-07-10 | 1980-08-19 | Warner-Lambert Company | 1-(4-Fluorophenyl)-4-(1,2,3,6-tetrahydro-4-phenoxy-1-pyridinyl)-butanones |
| US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
| US4221714A (en) * | 1979-08-03 | 1980-09-09 | American Cyanamid Company | 11-(1,2,3,6-Tetrahydro-substituted-4-pyridyl)-dibenz[b,f][1,4]oxazepines |
| US4305944A (en) * | 1980-09-08 | 1981-12-15 | Mead Johnson & Company | N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones |
-
1981
- 1981-03-16 US US06/244,426 patent/US4320131A/en not_active Expired - Fee Related
-
1982
- 1982-03-08 NZ NZ199944A patent/NZ199944A/en unknown
- 1982-03-09 ZA ZA821541A patent/ZA821541B/xx unknown
- 1982-03-11 FR FR8204101A patent/FR2501689B1/fr not_active Expired
- 1982-03-11 GR GR67561A patent/GR76113B/el unknown
- 1982-03-11 NL NL8201022A patent/NL8201022A/nl not_active Application Discontinuation
- 1982-03-12 AU AU81335/82A patent/AU535385B2/en not_active Ceased
- 1982-03-12 DK DK112682A patent/DK161322C/da not_active IP Right Cessation
- 1982-03-12 FI FI820855A patent/FI71317C/fi not_active IP Right Cessation
- 1982-03-15 IT IT47992/82A patent/IT1148145B/it active
- 1982-03-15 IL IL65254A patent/IL65254A0/xx not_active IP Right Cessation
- 1982-03-15 HU HU86477A patent/HU193379B/hu not_active IP Right Cessation
- 1982-03-15 HU HU82780A patent/HU190793B/hu not_active IP Right Cessation
- 1982-03-15 IE IE590/82A patent/IE52789B1/en not_active IP Right Cessation
- 1982-03-15 PH PH26997A patent/PH18182A/en unknown
- 1982-03-15 YU YU558/82A patent/YU43789B/xx unknown
- 1982-03-15 LU LU84012A patent/LU84012A1/fr unknown
- 1982-03-15 BE BE0/207573A patent/BE892502A/fr not_active IP Right Cessation
- 1982-03-15 CA CA000398330A patent/CA1192556A/en not_active Expired
- 1982-03-15 SE SE8201630A patent/SE449100B/sv not_active IP Right Cessation
- 1982-03-15 ES ES510448A patent/ES510448A0/es active Granted
- 1982-03-15 PT PT74584A patent/PT74584B/pt not_active IP Right Cessation
- 1982-03-16 CH CH4177/85A patent/CH657365A5/de not_active IP Right Cessation
- 1982-03-16 DE DE19823209534 patent/DE3209534A1/de active Granted
- 1982-03-16 AT AT0104682A patent/AT381939B/de not_active IP Right Cessation
- 1982-03-16 JP JP57040316A patent/JPS57165384A/ja active Granted
- 1982-03-16 GB GB8207580A patent/GB2094801B/en not_active Expired
- 1982-03-16 KR KR8201128A patent/KR880001557B1/ko not_active Expired
- 1982-03-16 CY CY137282A patent/CY1372A/en unknown
- 1982-03-16 CH CH1654/82A patent/CH652123A5/de not_active IP Right Cessation
- 1982-07-31 KE KE3710A patent/KE3710A/xx unknown
-
1986
- 1986-07-21 SE SE8603177A patent/SE460606B/sv not_active IP Right Cessation
-
1987
- 1987-03-27 SG SG308/87A patent/SG30887G/en unknown
-
1988
- 1988-01-21 HK HK46/88A patent/HK4688A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4423049A (en) | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines | |
| US5153206A (en) | Arylpiperidine derivatives | |
| CZ290056B6 (cs) | Derivát piperazinylcyklohexanolu a piperidylcyklohexanolu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
| KR880002011B1 (ko) | 2-[4-[(4,4-디알킬-2,6-피페리디온-1-일)부틸]-1-피페라지닐]피리딘 및 그의 제조방법 | |
| DE3522579C2 (de) | Neue 1,4-Dihydropyridin-Derivate und Salze derselben, Verfahren zur Herstellung derselben und pharmazeutische Mittel mit einem Gehalt derselben | |
| EP0029707B1 (en) | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them | |
| TW401417B (en) | 4-Aryloxy- and 4-arylthiopiperidine derivatives | |
| NL8201022A (nl) | Azaspiroalkaandionen; werkwijze voor het bereiden daarvan; farmaceutische preparaten; werkwijze voor het oproepen van een tranquilizereffect. | |
| US4677104A (en) | Antipsychotic fused-ring pyridinylpiperazine derivatives | |
| CA2460822C (en) | Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing same | |
| US5077295A (en) | Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides | |
| EP0220917B1 (en) | 1,4-dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof | |
| DE2643671A1 (de) | 4-phenylpiperidinyl- und 4 phenyltetrahydropyridinyl-alkylamino-ketoalkancarbonsaeuren und ihre salze mit saeuren und basen | |
| Boyle et al. | Structure-activity relationship studies: M2 and CCR5 receptor antagonists | |
| JPH11506131A (ja) | ヒンダードアミン光安定剤 | |
| Welstead Jr et al. | Aroylakylpyrrolidines. Central nervous system depressants | |
| KR820000582B1 (ko) | 인돌 유도체의 제조방법 | |
| FI57945B (fi) | Analogifoerfarande foer framstaellning av nya terapeutiskt aktiva 1-(1-(2-hydroxipropyl)-piperidyl-(4))-imidazolidinon-(2)- och -hexahydro-pyrimidinon-(2)-derivat | |
| NZ222517A (en) | 1-benzooxacycloalkylpyridine carboxylic acid derivatives, intermediates, and pharmaceutical compositions | |
| BE866710A (nl) | N-fenyl-n-(4-piperidinyl)amiden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: BRISTOL-MYERS SQUIBB COMPANY |
|
| BV | The patent application has lapsed |